Rhumbline Advisers lifted its holdings in shares of Amedisys Inc (NASDAQ:AMED) by 16.2% in the 4th quarter, HoldingsChannel reports. The firm owned 65,009 shares of the health services provider’s stock after acquiring an additional 9,058 shares during the period. Rhumbline Advisers’ holdings in Amedisys were worth $3,427,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently modified their holdings of the company. LS Investment Advisors LLC boosted its stake in Amedisys by 233.1% in the fourth quarter. LS Investment Advisors LLC now owns 3,564 shares of the health services provider’s stock worth $188,000 after buying an additional 2,494 shares in the last quarter. NorthCoast Asset Management LLC purchased a new stake in Amedisys in the third quarter worth approximately $262,000. Fox Run Management L.L.C. purchased a new stake in Amedisys in the fourth quarter worth approximately $269,000. Crossmark Global Holdings Inc. purchased a new stake in Amedisys in the third quarter worth approximately $341,000. Finally, Royal Bank of Canada boosted its stake in Amedisys by 1,320.7% in the second quarter. Royal Bank of Canada now owns 6,237 shares of the health services provider’s stock worth $392,000 after buying an additional 5,798 shares in the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.
Several analysts have issued reports on AMED shares. William Blair reaffirmed an “outperform” rating on shares of Amedisys in a research note on Tuesday, November 21st. BidaskClub lowered Amedisys from a “sell” rating to a “strong sell” rating in a research note on Thursday, January 11th. Zacks Investment Research raised Amedisys from a “hold” rating to a “buy” rating and set a $62.00 target price for the company in a research note on Monday, January 22nd. TheStreet lowered Amedisys from a “b” rating to a “c+” rating in a research note on Wednesday, February 28th. Finally, Robert W. Baird set a $66.00 target price on Amedisys and gave the stock a “hold” rating in a research note on Thursday, March 1st. Five research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $63.18.
Shares of Amedisys Inc (AMED) opened at $61.38 on Thursday. The firm has a market capitalization of $2,093.46, a P/E ratio of 69.75, a PEG ratio of 1.05 and a beta of 0.62. Amedisys Inc has a 52 week low of $45.60 and a 52 week high of $65.91. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.45 and a current ratio of 1.45.
Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Tuesday, February 27th. The health services provider reported $0.56 earnings per share for the quarter, missing analysts’ consensus estimates of $0.58 by ($0.02). The company had revenue of $404.24 million for the quarter, compared to analysts’ expectations of $394.96 million. Amedisys had a net margin of 1.98% and a return on equity of 15.14%. During the same period last year, the company posted $0.44 EPS. sell-side analysts forecast that Amedisys Inc will post 3 EPS for the current year.
WARNING: This piece of content was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/03/15/amedisys-inc-amed-stake-lifted-by-rhumbline-advisers.html.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.